All In Biotech

Investigational drug · Phase 2

DL001Z-NH

Also called: F2H23D, F2H23B, F2H23A

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza, Human.

Phase 2

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "DL001Z-NH"

First trial start

2024

May 23, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DL001Z-NH", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Influenza, Human

Approved drugs for the same conditions: Influenza · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "DL001Z-NH" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Influenza, Human

  • GP681Phase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • GP681 SimulantPhase 32 trials

    Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza

  • Flu mRNAGSK6479720A, GSK6498032APhase 22 trials

    GSK · Influenza, Human

  • ARCT-2304Phase 21 trial

    Arcturus Therapeutics, Inc. · Influenza, Human

  • DL001ZF2G22B, F2H23HPhase 21 trial

    GSK · Influenza, Human

  • GSK5800544APhase 21 trial

    GSK · Influenza, Human

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.